Nasdaq · Biological Products, (No Diagnostic Substances)
American biopharmaceutical company
83 entities across 41 jurisdictions, 2 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-24 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Asegua Therapeutics LLC | United States | |
| Calla Holdings, LLC | United States | |
| Calla Merger Sub, Inc. | United States | |
| CymaBay Therapeutics, Inc. | United States | |
| Forty Seven, LLC | United States | |
| Forty Seven Holdings, LLC | United States | |
| Gilead Alberta, LLC | United States | |
| Gilead Apollo, LLC | United States | |
| Gilead Biopharmaceutics US LLC | United States | |
| Gilead Calistoga, LLC | United States | |
| Gilead Connecticut, Inc. | United States | |
| Gilead Holdings, LLC | United States | |
| Gilead Pharmasset LLC | United States | |
| Gilead Sciences, LLC | United States | |
| Gilead Sciences Holding, LLC | United States | |
| Immunomedics, Inc. | United States | |
| IBC Pharmaceuticals, Inc. | United States | |
| Interius Biotherapeutics, Inc. | United States | |
| Kite Pharma, Inc. | United States | |
| Kite Pharma, LLC | United States | |
| neoKite, Inc. | United States | |
| Tmunity Therapeutics, Inc. | United States | |
| XinThera, Inc. | United States | |
| Gilead Sciences Argentina S.R.L. | Argentina | |
| Cytopia Pty. Ltd. | Australia | |
| Gilead Sciences Pty. Ltd. | Australia | |
| Gilead Sciences YM Australia Pty. Ltd. | Australia | |
| YM BioSciences Australia Pty. Ltd. | Australia | |
| Gilead Sciences GesmbH | Austria | |
| Gilead Sciences Belgium BV | Belgium | |
| Gilead Sciences Farmacêutica do Brasil Ltda. | Brazil | |
| CymaBay Canada, Ltd. | Canada | |
| Gilead Alberta ULC | Canada | |
| Gilead Sciences Canada, Inc. | Canada | |
| Gilead YM ULC | Canada | |
| Gilead Sciences (Shanghai) Consulting Co., Ltd. | China | |
| Gilead Sciences Hangzhou Pharmaceutical Co., Ltd. | China | |
| Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd. | China | |
| Gilead Sciences Colombia S.A.S. | Colombia | |
| Gilead Sciences s.r.o. | Czech Republic | |
| Gilead Sciences Denmark ApS | Denmark | |
| Gilead Sciences Finland Oy | Finland | |
| Gilead Sciences SAS | France | |
| Gilead Sciences GmbH | Germany | |
| Immunomedics GmbH | Germany | |
| MYR GmbH | Germany | |
| Gilead Sciences Hellas EPE | Greece | |
| Gilead Sciences Hong Kong Limited | Hong Kong | |
| Gilead Sciences India Private Limited | India | |
| CymaBay Ireland, Limited | Ireland | |
| Gilead Apollo Unlimited Company | Ireland | |
| Gilead Biopharmaceutics Ireland UC | Ireland | |
| Gilead Sciences Ireland Unlimited Company | Ireland | |
| Gilead Therapeutics A1 Unlimited Company | Ireland | |
| Gilead Sciences Israel Limited | Israel | |
| Gilead Sciences S.r.l. | Italy | |
| Gilead Sciences KK | Japan | |
| Gilead Sciences Luxembourg S.a.r.l. | Luxembourg | offshore centre |
| Gilead Sciences Malaysia Sdn. Bhd. | Malaysia | |
| Gilead Sciences Mexico S. de R.L. de C.V. | Mexico | |
| Gilead Sciences Netherlands B.V. | Netherlands | |
| Kite Pharma EU B.V. | Netherlands | |
| KP EU C.V. | Netherlands | |
| Gilead Sciences (NZ) | New Zealand | |
| Gilead Sciences Norway AS | Norway | |
| Gilead Sciences Americas S. de R.L. | Panama | offshore centre |
| Gilead Sciences Poland Sp. z.o.o. | Poland | |
| Gilead Sciences, Lda. | Portugal | |
| Gilead Sciences (GSR) S.R.L. | Romania | |
| Gilead Sciences Russia LLC | Russia | |
| Gilead Sciences Arabia Limited Company | Saudi Arabia | |
| Gilead Sciences Singapore Pte. Ltd. | Singapore | |
| Gilead Sciences South Africa (Pty) Ltd. | South Africa | |
| Gilead Sciences Korea Limited | South Korea | |
| Gilead Sciences S.L.U. | Spain | |
| Gilead Sciences Sweden AB | Sweden | |
| Gilead Sciences Switzerland Sarl | Switzerland | |
| Gilead Sciences Ilac Ticaret Limited Sirketi | Turkey | |
| CymaBay UK, Ltd. | United Kingdom | |
| Gilead Sciences Europe Limited | United Kingdom | |
| Gilead Sciences International Limited | United Kingdom | |
| Gilead Sciences Limited | United Kingdom | |
| MiroBio Ltd. | United Kingdom |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $24.7B | $123.0M | $7.5B | — | 1,263,000,000 |
| FY2021 | $27.3B | $6.2B | $10.8B | — | 1,262,000,000 |
| FY2022 | $27.3B | $4.6B | $8.3B | — | 1,262,000,000 |
| FY2023 | $27.1B | $5.7B | $7.4B | — | 1,258,000,000 |
| FY2024 | $28.8B | $480.0M | $10.3B | — | 1,255,000,000 |
| FY2025 | $29.4B | $8.5B | $9.5B | — | 1,255,000,000 |
16 institutions tracked — 8 added, 7 reduced, 1 opened a new position. Index money added 4,530,692 shares while active managers cut 15,436,298.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | Active fund | 21,353,121 | −13,018,789 | $2.7B |
| FMR LLC | Active fund | 66,870,816 | −5,035,474 | $8.4B |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 29,996,694 | +3,748,586 | $3.8B |
| BlackRock, Inc. | Index | 121,844,108 | +2,833,135 | $15.4B |
| Point72 Asset Management, L.P. | Hedge fund | 1,479,385 | +1,409,477 | $186.9M |
| STATE STREET CORP | Index | 61,216,552 | +1,357,967 | $7.7B |
| BANK OF AMERICA CORP /DE/ | Active fund | 18,649,065 | −1,329,871 | $2.4B |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 12,699,683 | −838,308 | $1.6B |
| MORGAN STANLEY | Active fund | 24,004,354 | +705,059 | $3.0B |
| CITADEL ADVISORS LLC | Hedge fund | 5,576,044 | −487,641 | $704.5M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 695,432 | −469,371 | $86.9M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 30,065,642 | +339,590 | $3.8B |
| Capital World Investors | Active fund | 40,988,975 | −294,958 | $5.2B |
| Bridgewater Associates, LP | Hedge fund | 290,881 | +110,144 | $36.7M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 2,217,376 | +64,848 | $280.1M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
GILEAD SCIENCES, INC. files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
